[{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"University of Alberta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onco-Innovations \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ University of Alberta"}]

Find Clinical Drug Pipeline Developments & Deals by Onco-Innovations

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The agreement aims to expand the research scope of its second-generation nanoparticle formulation of its Polynucleotide Kinase 3'-Phosphatase Inhibitor technology to encompass hard-to-treat cancers.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 13, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : University of Alberta

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The outcome of the study validated the potential of the PNKP Compound as a potent, single-agent therapy in combating colorectal cancer, specifically in cases where tumours exhibit PTEN deficiencies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Onco-Innovations Limited announces exclusive licensing of PNKP inhibitors to enhance cancer treatment by targeting DNA repair mechanisms, aiming to improve radiation therapy effectiveness.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank